Last reviewed · How we verify
IGF1R antibody MK0646
At a glance
| Generic name | IGF1R antibody MK0646 |
|---|---|
| Sponsor | Hillel Yaffe Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer (PHASE1, PHASE2)
- Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
- MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGF1R antibody MK0646 CI brief — competitive landscape report
- IGF1R antibody MK0646 updates RSS · CI watch RSS
- Hillel Yaffe Medical Center portfolio CI